CYTOXAN Drug Patent Profile

« Back to Dashboard

Which patents cover Cytoxan, and when can generic versions of Cytoxan launch?

Cytoxan is a drug marketed by Baxter Hlthcare and is included in two NDAs.

The generic ingredient in CYTOXAN is cyclophosphamide. There is one drug master file entry for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cytoxan

A generic version of CYTOXAN was approved as cyclophosphamide by BAXTER HLTHCARE on May 21^st, 2008.

Summary for CYTOXAN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	1,025
Patent Applications:	4,935
DailyMed Link:	CYTOXAN at DailyMed

Recent Clinical Trials for CYTOXAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Incyte Corporation	PHASE2
Fred Hutchinson Cancer Center	PHASE2
Medical University of South Carolina	PHASE2

See all CYTOXAN clinical trials

US Patents and Regulatory Information for CYTOXAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	CYTOXAN	cyclophosphamide	INJECTABLE;INJECTION	012142-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Baxter Hlthcare	CYTOXAN (LYOPHILIZED)	cyclophosphamide	INJECTABLE;INJECTION	012142-005	Aug 30, 1982		DISCN	Yes	No
Baxter Hlthcare	CYTOXAN	cyclophosphamide	TABLET;ORAL	012141-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes
Baxter Hlthcare	CYTOXAN (LYOPHILIZED)	cyclophosphamide	INJECTABLE;INJECTION	012142-009	Dec 10, 1985		DISCN	Yes	No
Baxter Hlthcare	CYTOXAN	cyclophosphamide	INJECTABLE;INJECTION	012142-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Baxter Hlthcare	CYTOXAN	cyclophosphamide	TABLET;ORAL	012141-002	Approved Prior to Jan 1, 1982		RX	Yes	No

CYTOXAN Market Dynamics, Financial Trajectory, Patent Estate, and Generic Competition

Last updated: October 15, 2026

Cytoxan is the branded version of cyclophosphamide, an alkylating agent used in oncology, autoimmune disease, and conditioning regimens. Its commercial profile is mature: core patents and regulatory exclusivity expired decades ago, generic cyclophosphamide dominates volume, and no standalone Cytoxan revenue is publicly reported. Current market value is driven by low-cost generic demand, sterile-injectable supply conditions, hospital purchasing, and clinical use in combination therapies rather than by brand pricing power.

What is Cytoxan and how is cyclophosphamide used?

Cytoxan contains cyclophosphamide, a nitrogen-mustard prodrug that is metabolized to active alkylating compounds. It is available as oral tablets and as an intravenous injection or powder for reconstitution.

Approved and established uses include:

• Non-Hodgkin lymphoma, multiple myeloma, leukemia, and breast cancer
• Nephrotic syndrome in selected pediatric patients
• Severe autoimmune disorders, including lupus and vasculitis, generally under specialist supervision
• Hematopoietic stem-cell transplantation and other conditioning protocols
• Combination regimens such as CHOP, R-CHOP, AC, CMF, and high-dose chemotherapy protocols

The FDA-approved label identifies cyclophosphamide as a component of combination chemotherapy and as a treatment for selected immune-mediated diseases. Clinical demand is therefore distributed across oncology, hematology, rheumatology, nephrology, and transplant medicine rather than concentrated in one indication (U.S. Food and Drug Administration [FDA], 2024a).

What is the FDA and Orange Book status of Cytoxan?

Cytoxan is an established small-molecule drug with no meaningful current regulatory exclusivity.

Regulatory attribute	Cytoxan and cyclophosphamide status
Active ingredient	Cyclophosphamide
Dosage forms	Oral tablets; intravenous injection or powder
Original U.S. approval	1959
Original NDA	NDA 012141
Regulatory pathway	New drug application, followed by extensive generic competition
Current exclusivity	None of commercial significance
Orange Book role	Identifies approved reference products and generic equivalents
Biosimilar pathway	Not applicable
Current market structure	Brand, authorized or branded-generic products, and multiple ANDA products

The relevant competitive pathway is an abbreviated new drug application, not a biosimilar application. Cyclophosphamide is a chemically synthesized small molecule, so generic manufacturers establish equivalence under the ANDA framework. The FDA Orange Book lists approved products and patent or exclusivity information where applicable; the original Cytoxan patent estate no longer provides a practical barrier to generic entry (FDA, 2024b).

When did Cytoxan lose exclusivity?

Cytoxan lost meaningful market exclusivity many years ago. The product was approved in the late 1950s, and generic cyclophosphamide became available after expiration of the original patent and regulatory protections.

The commercial timeline is:

Period	Event	Market effect
1959	FDA approval of cyclophosphamide/Cytoxan	Originator market established
1970s-1980s	Original compound and formulation protections expired or became commercially irrelevant	Generic development became possible
1980s onward	Generic oral and injectable cyclophosphamide expanded	Brand pricing power declined
2000s-2010s	Hospital and oncology purchasing shifted toward generic supply	Cytoxan became a mature product
2020s	Supply interruptions affected several generic injectables	Availability, not patent exclusivity, became the primary market issue

No current patent term extension or pediatric exclusivity materially changes the commercial outlook. Any remaining patents associated with legacy cyclophosphamide products would not create a meaningful barrier to ordinary generic competition.

What patents protect Cytoxan today?

No commercially significant active patent is known to protect the core Cytoxan molecule, standard cyclophosphamide formulations, or ordinary generic manufacturing.

The original patent position covered the active compound and early pharmaceutical use. Those rights expired long before the current market period. The patent estate is therefore weak by branded-pharmaceutical standards.

Patent category	Current relevance
Cyclophosphamide composition patents	Expired
Conventional oral tablet patents	Expired or commercially irrelevant
Standard injectable formulation patents	No material blocking position
Method-of-use patents	No broad, enforceable exclusivity covering established indications
Manufacturing patents	Potentially relevant to individual suppliers, but not a broad market barrier
Device or delivery patents	Limited relevance because Cytoxan is primarily a tablet and hospital-administered injectable

The primary intellectual-property risks for manufacturers are process confidentiality, supplier qualification, manufacturing know-how, and regulatory compliance. Those factors may delay a specific competitor but do not recreate originator exclusivity.

How many patents cover cyclophosphamide and Cytoxan?

Patent counts depend on the search database, jurisdiction, family consolidation, and whether expired patents are included. A raw search can return numerous historical documents, but those records do not represent active commercial protection.

For market analysis, the relevant conclusion is:

1. Historical cyclophosphamide patents exist.
2. The core composition and conventional product claims are expired.
3. No active patent family is known to block ordinary U.S. generic entry.
4. Current commercial differentiation depends on supply reliability, manufacturing economics, and customer contracts.

Patent-count databases should not be used without separating live claims from expired historical records. Counting every patent publication can materially overstate Cytoxan’s current protection.

Which companies compete with Cytoxan?

The United States market includes the legacy Cytoxan brand, generic cyclophosphamide tablets, and multiple injectable products. Supplier participation can change because of manufacturing economics, procurement contracts, and drug-shortage conditions.

Known or historically active suppliers include:

• Bristol Myers Squibb as the historical Cytoxan originator
• Baxter Healthcare
• Fresenius Kabi
• Hikma Pharmaceuticals
• Teva Pharmaceuticals
• Accord Healthcare
• Sagent Pharmaceuticals and related specialty-generic operations
• Other ANDA holders and regional hospital suppliers

The competitive set is not limited to cyclophosphamide. Physicians may substitute or sequence other agents depending on the indication:

Therapeutic need	Relevant alternatives
Lymphoma chemotherapy	Bendamustine, ifosfamide, chlorambucil, targeted agents, antibody-based regimens
Breast cancer chemotherapy	Doxorubicin, docetaxel, paclitaxel, carboplatin, fluorouracil
Autoimmune disease	Rituximab, mycophenolate, azathioprine, methotrexate, glucocorticoids
Transplant conditioning	Melphalan, busulfan, fludarabine, radiation-based protocols
Pediatric nephrotic syndrome	Glucocorticoids, calcineurin inhibitors, mycophenolate, rituximab

Cyclophosphamide remains difficult to displace completely because it is inexpensive, familiar to clinicians, available in multiple strengths and presentations, and incorporated into established treatment protocols.

What is the financial trajectory of Cytoxan?

Cytoxan does not have a separately disclosed revenue line in current Bristol Myers Squibb financial reporting. BMS reports products and franchises at an aggregate level, and mature legacy products are generally not broken out individually. As a result, no reliable public figure establishes current annual Cytoxan revenue.

Its financial trajectory is best characterized as follows:

Phase	Revenue profile	Main economic driver
Originator growth	High-margin branded sales	New indications and physician adoption
Generic entry	Rapid price and share erosion	ANDA competition
Mature generic market	Low unit economics, stable clinical demand	Volume, contracts, and manufacturing cost
Current market	Brand revenue limited; generic value fragmented	Hospital procurement and supply availability

The brand’s revenue exposure is likely immaterial relative to BMS’s major oncology franchises. The broader cyclophosphamide market continues to generate commercial value, but that value is distributed across generic manufacturers, wholesalers, hospitals, and health systems rather than captured by the original sponsor.

Public market-sizing reports often produce materially different estimates because they may combine branded and generic products, include multiple dosage forms, or count global sales at list prices rather than net prices. No audited public source provides a definitive global Cytoxan revenue figure.

What drives cyclophosphamide market demand?

Demand is relatively resilient because cyclophosphamide is embedded in treatment protocols and is used across several specialties.

The main demand drivers are:

• Continued use of R-CHOP and related lymphoma regimens
• Breast cancer combination therapies
• High-dose conditioning before stem-cell transplantation
• Severe autoimmune disease requiring immunosuppression
• Pediatric nephrotic syndrome treatment
• Use in countries where newer targeted agents are less affordable
• Hospital preference for established, low-cost injectable products

Demand is less sensitive to consumer advertising or brand loyalty than the market for chronic outpatient drugs. Treatment protocols, clinical guidelines, hospital formularies, and procurement agreements have greater influence.

What generic entry risks exist for Cytoxan?

Generic entry risk is effectively realized rather than prospective. The principal competitive risk is continued erosion of branded volume and price, not a future Paragraph IV event.

What is the Paragraph IV status of cyclophosphamide?

No major current Paragraph IV dispute is central to the Cytoxan market. Paragraph IV litigation is generally relevant when a generic applicant challenges an unexpired listed patent. Cytoxan’s core patents are expired, so the standard market-entry model is ordinary ANDA approval rather than a high-value patent challenge.

Potential legal disputes could still involve:

• Manufacturing processes
• Product quality
• Labeling or regulatory compliance
• Supply contracts
• Trademark use
• Product-liability claims
• Patent claims directed to a specialized formulation or new use

These issues do not restore exclusivity for conventional cyclophosphamide.

What formulation patents protect cyclophosphamide?

Conventional tablets and lyophilized or powdered injectable cyclophosphamide products have no known commercially significant formulation barrier comparable to modern extended-release or device-protected products.

The technical challenges are operational:

• Maintaining injectable sterility
• Controlling particulate matter and impurities
• Validating reconstitution and stability
• Managing hazardous-drug handling
• Ensuring consistent active pharmaceutical ingredient supply
• Meeting container-closure and packaging requirements

These requirements raise the cost of entry and can reduce the number of reliable suppliers, but they are regulatory and manufacturing barriers rather than patent exclusivity.

What manufacturing and supply risks affect the market?

Cyclophosphamide is a hazardous compound, and injectable production requires specialized containment, validated aseptic processing, and quality systems. The injectable market is more vulnerable than the tablet market to plant interruptions and supplier concentration.

The main supply risks include:

• Shortages of active pharmaceutical ingredient
• Sterile manufacturing shutdowns
• Limited capacity for hazardous-drug production
• Delays in quality testing or regulatory release
• Hospital inventory concentration
• Contract-manufacturing dependence
• Demand spikes caused by competitor shortages

FDA and American Society of Health-System Pharmacists shortage records have periodically identified cyclophosphamide injection availability concerns. Shortages can increase supplier leverage and temporarily raise transaction prices, but they do not create durable pricing power because multiple manufacturers and dosage forms remain available (FDA, 2024c; American Society of Health-System Pharmacists, 2024).

What is the biosimilar risk for Cytoxan?

Biosimilar risk is not applicable. Cytoxan is a small-molecule drug, not a biologic. Its competitors enter through ANDAs demonstrating pharmaceutical equivalence and bioequivalence.

The commercial risk is greater than biosimilar substitution in one respect: generic substitution has already been established for decades. Pharmacy substitution, hospital purchasing, and formulary controls have structurally reduced the role of the Cytoxan brand.

What licensing deals affect Cytoxan?

No recent licensing transaction is known to have materially changed the Cytoxan market. The product is a mature genericized medicine, and commercial arrangements are more likely to involve:

• Contract manufacturing
• Regional distribution
• Hospital purchasing agreements
• Generic portfolio acquisitions
• Supply and API contracts

The absence of a major current licensing deal is consistent with the product’s low exclusivity and limited brand growth opportunity. A transaction involving cyclophosphamide would be valued primarily on supply reliability, geographic rights, and manufacturing capacity rather than on patent duration.

What litigation affects Cytoxan?

No active, high-value patent litigation is central to the current Cytoxan commercial outlook. The relevant legal environment is ordinary mature-generic competition.

Litigation exposure remains possible in:

• Product liability, including secondary malignancy and infertility allegations
• Failure-to-warn claims
• Sterile-product quality disputes
• ANDA-related claims involving a new formulation or use
• Government pricing, rebate, or procurement disputes

The product label carries serious warnings, including myelosuppression, infection risk, infertility, hemorrhagic cystitis, secondary malignancies, and embryo-fetal toxicity. These warnings create liability exposure but do not materially support pricing or exclusivity (FDA, 2024a).

How does Cytoxan compare with newer oncology drugs?

Cytoxan has a weaker patent estate and lower price than newer targeted therapies. Its commercial advantages are clinical familiarity, broad protocol integration, global availability, and low acquisition cost.

Attribute	Cytoxan/cyclophosphamide	New targeted oncology drugs
Patent position	Largely expired	Often substantial active estate
Pricing	Generic and low-cost	Frequently high-cost
Substitution	Protocol and formulary driven	Biomarker and indication driven
Supply risk	Sterile manufacturing and API	Complex manufacturing and exclusivity
Revenue growth	Limited	Can be rapid during launch period
Clinical role	Backbone or component therapy	Often disease-specific or biomarker-selected

Cyclophosphamide is unlikely to produce major standalone growth. Its strategic value lies in persistent utilization across established regimens and in markets where cost containment favors generic chemotherapy.

What is the outlook for generic launch scenarios?

A new conventional generic entrant would face limited patent risk but substantial commercial pressure. The likely launch scenario is:

1. ANDA approval without meaningful Paragraph IV litigation.
2. Rapid price competition in tablet and injectable presentations.
3. Difficulty securing hospital contracts without dependable supply.
4. Low margins unless the entrant has efficient API sourcing or differentiated packaging.
5. Greater opportunity during a competitor shortage than during normal market conditions.

A differentiated formulation, ready-to-use injectable presentation, or reliable shortage-resistant supply could command better commercial terms. A conventional copy of an established presentation would face a crowded market.

Key Takeaways

• Cytoxan is the legacy brand for cyclophosphamide, a mature alkylating agent.
• Core patents and regulatory exclusivity expired decades ago.
• No current patent estate is known to block ordinary generic entry.
• Paragraph IV litigation is not a central current market issue.
• Biosimilar competition does not apply; ANDA-based generic competition does.
• BMS does not publicly disclose standalone Cytoxan revenue.
• The brand’s financial importance is limited relative to BMS’s major products.
• Generic cyclophosphamide demand remains supported by oncology, autoimmune, transplant, and pediatric use.
• Injectable supply reliability is a more important commercial variable than patent protection.
• Manufacturing capacity, sterile processing, API access, and hospital contracts determine competitive performance.

FAQs about Cytoxan market value and exclusivity

Is Cytoxan still sold as a branded drug?

Cytoxan has historically been sold as the branded cyclophosphamide product, but the commercial market is dominated by generic cyclophosphamide. Availability and labeling can vary by dosage form and supplier.

Does cyclophosphamide have any active U.S. patent protection?

No commercially significant core patent protection is known to block conventional generic cyclophosphamide products in the United States.

Can a pharmacy substitute generic cyclophosphamide for Cytoxan?

Substitution depends on the dosage form, state law, prescription instructions, and institutional policy. Hospitals commonly procure generic cyclophosphamide rather than the legacy brand.

Is cyclophosphamide affected by drug shortages?

Injectable cyclophosphamide can be affected by sterile-manufacturing interruptions, API constraints, and supplier concentration. Tablet availability is generally less exposed to the same operational risks.

Is Cytoxan a major revenue product for Bristol Myers Squibb?

No standalone current revenue figure is publicly reported, and Cytoxan is not a major disclosed contributor compared with BMS’s principal oncology and immunology franchises.

References

American Society of Health-System Pharmacists. (2024). Drug shortages: Cyclophosphamide injection. https://www.ashp.org/drug-shortages

Bristol Myers Squibb. (2024). 2023 annual report. https://www.bms.com/investors/annual-reports.html

U.S. Food and Drug Administration. (2024a). Cytoxan (cyclophosphamide) prescribing information. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Food and Drug Administration. (2024c). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/